Recruiting

iVAS

Sponsor:

NuPulseCV

Code:

NCT02645539

Conditions

Heart Failure NYHA Class III

Heart Failure NYHA Class IV

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

intravascular ventricular assist system (iVAS)

Study Details

Brief summary:

The purpose of this feasibility study is to assess the preliminary safety and clinical performance of the intravascular ventricular assist system (iVAS).

Conditions

Heart Failure NYHA Class III

Heart Failure NYHA Class IV

Study ID

NCT02645539

Start date

Apr, 2016

Status verified date

Nov, 2019

Completion date

Dec, 2020

Anticipated

Primary completion date

Jul, 2020

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Main Inclusion Criteria:

1. At least 18 years of age.
2. If female, are postmenopausal or surgically sterilized, or have a negative pregnancy test within seven (7) days of invasive testing.
3. Advanced heart failure (NYHA Class III or IV)

Main Exclusion Criteria:

1. Hypotension treated with the following medications: epinephrine, norepinephrine, vasopressin, methylene blue, phenylephrine, or angiotensin II.
2. Receiving more than two inotropes.
3. Subclavian stenosis or stent.
4. Currently receiving circulatory support including ECMO, Impella, TandemLife or equivalents; or any durable VAD.
5. Atrial fibrillation without ventricular pacing.
6. Concomitant, non-cardiac disease process with life expectancy < 1 year.
7. Significant abnormalities of the aorta, such as aneurysms, coarctation of the aorta, or an extremely tortuous aorta.
8. Severe end-organ dysfunction or failure.
9. Any other condition the heart team believes inappropriate for this study.

Study Design

Enrollment

100 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Single Arm

All patients are treated with the intravascular ventricular assist system (iVAS).

Interventions

intravascular ventricular assist system (iVAS)

A mechanical circulatory support device using the principles of counterpulsation.

Primary outcome measure

  • Survival to transplant or stroke-free survival [ Time Frame: 30 days ]

Central Contacts and Locations

Central contacts

Locations

MedStar Washington Hospital Center

Recruiting

Washington, District of Columbia, United States, 20010

Advent Health

Recruiting

Orlando, Florida, United States, 32804

University of Chicago Medicine

Recruiting

Chicago, Illinois, United States, 60637

NorthShore University Health System

Recruiting

Evanston, Illinois, United States, 60201

Saint Vincent Hospital

Recruiting

Indianapolis, Indiana, United States, 46260

University of Louisville

Recruiting

Louisville, Kentucky, United States, 40202

Ochsner Clinic Foundation

Recruiting

New Orleans, Louisiana, United States, 70121

Brigham & Women's Hospital

Recruiting

Boston, Massachusetts, United States, 02115

University of Minnesota

Recruiting

Minneapolis, Minnesota, United States, 55455

University of Nebraska

Recruiting

Omaha, Nebraska, United States, 68198

New York University

Recruiting

New York, New York, United States, 10016

Columbia University Medical Center / New York-Presbyterian Hospital

Recruiting

New York, New York, United States, 10032

Duke University

Recruiting

Durham, North Carolina, United States, 27710

Abington Hospital - Jefferson Health

Recruiting

Abington, Pennsylvania, United States, 19001

Penn State Health Milton S. Hershey Medical Center

Recruiting

Hershey, Pennsylvania, United States, 17033

Houston Methodist Research Institute

Recruiting

Houston, Texas, United States, 77030

University of Utah Hospital

Recruiting

Salt Lake City, Utah, United States, 84132

More Information

Sponsor

NuPulseCV

Last update posted

Nov 13, 2019

Last verified

Nov, 2019

Keywords

  • Heart failure
  • Bridge-to-transplant
  • circulatory support
  • VAD
  • IABP

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by NuPulseCV on 2019-11-13.